This retrospective study was undertaken to obtain information regarding the survival and toxicities after Yttrium-90 microspheres treatment in patients with primary liver malignancies. Baseline, treatment, and follow-up data were collected and analyzed for 21 patients treated with Yttrium-90 microspheres. Survival analysis was then performed. The results of this study showed that median survival for all the patients was 120 days. Twenty of 21 patients were categorized as high-risk with a median survival of 114 days. It was also found that one high-risk patient has survived 858 days with no recurrence of disease. Acute grade 3-5 toxicities were recorded for nine patients and consisted of elevations in AST and bilirubin, thrombocytopenia, abdominal pain, ascites, nausea, fatigue, and death. This study concluded that Yttrium-90 is a low-toxicity, outpatient alternative for individuals with liver cancer and without many options. The maximal value, however, may lie in the treatment of low-risk patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/153303460900800109 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing dosimetric accuracy in radioembolization: comparative effectiveness of SPECT/CT, planar imaging, and PET/CT for lung shunt fraction assessment.
Nucl Med Rev Cent East Eur
December 2024
Department of Radiology & Nuclear Medicine, Sultan Qaboos Comprehensive Cancer Care, and Research Center, Muscat, Oman.
Background: In radioembolization therapy for hepatic malignancies, the accurate estimation of lung shunt fraction (LSF) is crucial to minimize the risk of radiation-induced pneumonitis and fibrosis due to hepatopulmonary shunting of yttrium-90 (90Y)-microspheres. This study aimed to compare the accuracy and precision of LSF estimation using technetium-99m macroaggregated albumin single photon emission computed tomography ([99mTc]Tc-MAA SPECT) LSF, [99mTc]Tc-MAA planar LSF, and 90Y PET LSF in patients undergoing 90Y-radioembolization.
Material And Methods: A retrospective study was conducted involving 15 patients diagnosed with hepatocellular carcinoma (HCC) or liver metastases and planned to undergo transarterial radioembolization with 90Y SirSpheres after multidisplinary team discussion.
Transarterial Radioembolization with Yttrium-90 Resin Microspheres for Huge Focal Nodular Hyperplasia.
Cardiovasc Intervent Radiol
December 2024
Ytrrium-90 Precision Interventional Radiotherapy Center of Liver Cancer, SchoolofClinicalMedicine, Beijing Tsinghua Changgung Hospital, TsinghuaUniversity, Beijing, China.
Prediction of left lobe hypertrophy with voxel-based dosimetry using integrated Y-90 PET/MRI after radioembolization of liver tumors with Y-90 microspheres.
Eur J Nucl Med Mol Imaging
December 2024
Ankara University Medical School Department of Nuclear Medicine, Ankara, Turkey.
Purpose: The aim of this study was to investigate the relationship between voxel-based dosimetric variables derived from Y-90 PET/MRI and hypertrophy observed in the left lobe after radioembolization and to investigate if there is any difference in hypertrophy induced by glass versus resin microspheres.
Methods: Voxel-based dosimetry-derived variables and their relationship with the change of the standardized future liver remnant (ΔFLR) was investigated with linear regression models. To compare and evaluate the discriminatory power of the dosimetric variables, ROC analyses were utilized.
Case Report: Successful Treatment of Solitary Fibrous Tumor with Selective Internal Radiation Therapy (SIRT).
Diseases
November 2024
Department of Oncology, Emek Medical Center, Yitzhak Rabin Boulevard 21, Afula 1834111, Israel.
: This case report details the innovative use of selective internal radiation therapy (SIRT) with Yttrium-90 resin microspheres to treat a 73-year-old woman with a solitary fibrous tumor (SFT), a rare and challenging tumor type. SFTs often present significant treatment difficulties, especially in cases of recurrence or metastasis, as systemic therapies typically show limited effectiveness. This report explores SIRT as an alternative therapeutic approach for SFTs with liver metastasis.
View Article and Find Full Text PDFYttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma.
World J Radiol
October 2024
Department of Radiology, The Ohio State University Medical Center, Columbus, OH 43210, United States.
As the third leading cause of cancer-related deaths worldwide, hepatocellular carcinoma (HCC) represents a significant global health challenge. This paper provides an introduction and comprehensive review of transarterial radioembolization (TARE) with Yttrium-90 (Y90), a widely performed transcatheter procedure for HCC patients who are not suitable candidates for surgery. TARE involves the targeted delivery of radioactive microspheres to liver tumors, offering a promising treatment option for managing HCC across various stages of the disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!